07:21 AM EDT, 09/02/2025 (MT Newswires) -- IDEAYA Biosciences ( IDYA ) said Tuesday it has entered into an exclusive license agreement with France-based pharmaceutical group Servier for darovasertib, a treatment of uveal melanoma, a rare type of eye cancer.

Under the agreement, Servier will make an upfront payment of $210 million to IDEAYA for the regulatory and commercial rights for darovasertib in all territories outside the US.

IDEAYA will be eligible for up to $320 million in regulatory and commercial milestone payments, as well as royalties, and will retain the rights for darovasertib in the US.

The parties also plan to collaborate on the development of darovasertib and share the associated costs, IDEAYA said.

IDEAYA shares were up 11% in recent Tuesday premarket activity.